Podium to Practice: ESMO® 2026 – Breast: TALENT
OR
Studies / Trials Discussed
LBA23 – Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
Explore more from your favourite experts – click their name to access their entire library of content.
This program has been made possible through unrestricted support from Novartis.
Studies/trials discussed:
LBA23 – Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.